Zhejiang Shapuaisi Pharmaceutical (603168.SH): Olodaterol hydrochloride eye drops obtained drug registration certificate
Shapuaisi (603168.SH) announced that the company has received approval from the National Medical Products Administration for the issuance of hydrochloride...
Zhejiang Shapuaisi Pharmaceutical (603168.SH) announced that the company has received the Drug Registration Certificate for Olopatadine Hydrochloride Eye Drops approved and issued by the National Medical Products Administration. The approved Olopatadine Hydrochloride Eye Drops are used to treat eye itching related to allergic conjunctivitis.
Related Articles
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
